NCT06113809View on ClinicalTrials.gov

Palbociclib and Pembrolizumab in Sarcoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Sarcoma
Interventions
DRUG

Palbociclib

"Palbociclib is a CDK4/6 inhibitor.~Palbociclib, 125 mg, (pediatric dose 75mg/m2 up to 125mg) daily for 21 days out of every 28 days, PO (orally) starting 14 days prior to Pembrolizumab"

DRUG

Pembrolizumab

"Pembrolizumab is a PD-1 blocking antibody.~Given 14 days following Palbociclib: Pembrolizumab, 200 mg, once every three weeks, intravenously (IV)"

Trial Locations (1)

52242

RECRUITING

University of Iowa Hospitals & Clinics, Iowa City

All Listed Sponsors
lead

John Rieth

OTHER